SUNDAY, MAY 31, 2026
8:30am – 9:30am
IBD
Case Presentations (Interactive)
Moderator:
Dr. Jeffrey McCurdy, MD PhD FRCPC
Assistant Professor of Medicine, University of Ottawa
Clinical Investigator, The Ottawa Research Institute
Dr. Jeffrey McCurdy received his PhD in Immunology from Dalhousie University and MD from the University of Ottawa. He completed Gastroenterology training at Dalhousie University, and an advanced fellowship in IBD at Mayo Clinic, Rochester.
He is co-chair of IBD update (ibdupdate.ca), co-editor of the journal Canadian IBD Today and recent recipient of the 2025 Canadian Association of Gastroenterology visiting professor award.
His research interests focus on identifying predictors of disease related outcomes in IBD, including perianal Crohn’s disease, infectious exacerbations of IBD and venous thromboembolism.
Speaker #1:
Parakkal Deepak MD, MS, FACG
Professor of Medicine
Co-Director Inflammatory Bowel Diseases Center
Director, Advanced IBD Fellowship
Director of Clinical and Translational Research for the Division of Gastroenterology
Washington University School of Medicine, St. Louis, Missouri, USA
Parakkal Deepak, MBBS, MS, FACG is currently a physician-scientist in the Inflammatory Bowel Disease (IBD) Center in the Division of Gastroenterology at the Washington University School of Medicine (WUSM) in St. Louis, Missouri where he is a Professor of Medicine, Co-Director of the IBD center and Director of Clinical and Translation research for the Division of Gastroenterology. He is a Fellow of ACG and has been recognized as a ‘AGA Future Leader’ and elected as Vice Chair of the Immunology, Microbiology and Inflammatory Bowel Diseases Section of the the American Gastroenterological Association. He also serves as the Deputy Director of Data Quality and Enhancement of the prospective longitudinal biobanking cohort, the SPARC-IBD of the Crohn’s and Colitis Foundation and on the core ‘Operations Group’ of the International TOpCLASS Fistula Consortium.
The overarching research focus is refractory inflammatory bowel disease. Within this a key focus area of research is Obesity, its impact and cardiometabolic syndrome in IBD, where his group has made novel observations in prevalence of MASLD, risk of cirrhosis, performance of current ASCVD prediction tools and is investigating the impact of GLP1RAs in patients with IBD through a prospective study funded by Helmsley Trust. His additional research focus is perianal Crohn’s disease, funded by the American Gastroenterological Association, the Leona M. and Harry B. Helmsley Charitable Trust and the Litwin grant of the Crohn’s and Colitis Foundation, apart from investigator-initiated grants funded by industry and philanthropic funding from Leo & Carean Goss Crohn’s Disease Research Fund . Here co-leads a bench-bedside basic-translational-clinical group focused on improving the precision of care in perianal CD through single cell RNAseq and spatial transcriptomics, radiomics from fistula MRI pelvis, standard PET MR/novel tracers and 3D print applications. Additional He is also investigating imaging of inflammation and fibrosis in small bowel CD through novel PET tracers to CCR2 and FAPI.
He has co-founded the REBOOT IBD consortium across 11 leading IBD centers in the United States to publish real-world data on outcomes with newest advanced therapies in IBD.
Speaker #2:
Dr. David K. Wong, MD, FRCP(C)
Hepatologist
Clinical Director, Toronto Western Hospital Francis Family Liver Center
University Health Network, Assistant Professor of Medicine
University of Toronto, Toronto, ON
Dr. David Wong is a hepatologist in Toronto, Ontario. He graduated from the University Of Toronto Faculty Of Medicine in 1988. Following his clinical training in Internal Medicine and Gastroenterology, Dr. Wong received further training as a research fellow with Dr. Bruce Walker at the Massachusetts General Hospital, Harvard Medical School, where he studied the cellular immune responses to hepatitis C viral infection.
Dr. Wong was initially appointed full time staff in the Division of Gastroenterology at McMaster University in 2000 and then moved to the University Health Network (UHN)/Mount Sinai Hospital (MSH) in 2002, where he is the Clinical Director of the Toronto Western Hospital Francis Family Liver Center, University Health Network. He is also on staff of the Immunodeficiency Clinic at UHN - Toronto General Division and is currently an Assistant Professor of Medicine at the University of Toronto. He is also the staff hepatologist at the Specialized Positive Care Clinic at St. Michael’s Hospital.
Dr. Wong's clinical interests lie in the area of viral hepatitis and liver disease in HIV. His educational responsibilities include coordinating the Clinical Hepatology training program for the University of Toronto. He is an advisor to the Hepatitis C Secretariat at the Ministry of Health and Long-Term Care. Dr. Wong also co-ordinates the annual Hepatology Update meeting in Toronto.
Speaker #3:
Dr. Sanjay Murthy, MD, MSc (Epid), FRCPC
Associate Professor, Department of Medicine and School of Epidemiology and Public Health, University of Ottawa
Staff Gastroenterologist, The Ottawa Hospital Inflammatory Bowel Diseases Centre
Scientist, Clinical Epidemiology Program, Ottawa Hospital Research Institute
Adjunct Scientist, ICES uOttawa
Dr. Murthy is an Associate Professor and Clinician-Scientist in the Department of Medicine at the University of Ottawa and Gastroenterologist at the Ottawa Hospital IBD Centre. He completed his MD at the University of Ottawa, Internal Medicine Training at the University of Manitoba and Gastroenterology Training at the University of Toronto. He has completed advanced fellowships in IBD (Mount Sinai Hospital, Toronto), diagnostic endoscopy (University of Mainz, Germany), clinical nutrition (Toronto General Hospital) and intestinal ultrasound (Brisbane, Melbourne) and an M.Sc. degree in Clinical Epidemiology and Health Care Research (University of Toronto). Dr. Murthy’s clinical practice is in IBD and general gastroenterology. His research program focuses on population-based observational studies, pragmatic trials and clinical prediction models to the study inflammatory bowel diseases and gastrointestinal cancers. He is supported by a Faculty of Medicine Research Chair in IBD from the University of Ottawa.